Introduction: Why Brand Similarity Is a Business Risk
In highly regulated industries like pharmaceuticals, branding decisions can directly impact market trust, regulatory compliance, and long-term business value.
In a significant ruling, the Bombay High Court granted interim relief to Sun Pharmaceutical Industries Ltd., restraining another company from using the mark “Pantozed-40.” The Court found the name deceptively similar to Sun Pharma’s well-known brand “Pantocid.”
For businesses, this ruling sends a clear message:
Choosing a brand name without adequate IP due diligence can lead to costly disputes, product disruption, and reputational damage.
The Core Issue: Similar Names Create Market Risk
The dispute centered around the similarity between:
- Pantocid – an established anti-acidity medication
- Pantozed-40 – a newer product using a similar name and the same active ingredient
The Court observed that the names shared:
- A similar prefix (“Panto”)
- A phonetically similar ending (“cid” vs “zed”)
From a business perspective, this similarity increases:
- Consumer confusion
- Prescription errors
- Brand dilution
- Liability risks
In pharmaceutical markets, even minor confusion can translate into serious public health consequences, making courts especially strict in such matters.
Why Sun Pharma Succeeded: Strength of Established Branding
Sun Pharma successfully demonstrated that:
- The brand Pantocid had been used since 1998
- The product had developed significant market goodwill
- The competing brand entered the market much later
- The competing party lacked strong trademark protection in India
For businesses, this highlights a fundamental principle:
Long-term brand building combined with early trademark protection creates strong legal and commercial advantages.
A Key Business Insight: Export Use Still Counts as Brand Use
One of the most important commercial takeaways from the case relates to export operations.
The defendant argued that:
- The product was manufactured in India
- But intended only for export
- Therefore, it should not count as trademark use in India
The Court rejected this argument and clarified:
Manufacturing in India—even for export—still qualifies as trademark use.
Business Impact:
Companies involved in:
- Contract manufacturing
- Export-focused production
- Global supply chains
must ensure their brand names do not conflict with existing trademarks in the manufacturing jurisdiction.
Passing Off vs Infringement: Understanding Commercial Exposure
While the Court granted relief for trademark infringement, it did not uphold the passing off claim.
Why?
Because the product was not sold in India, there was no evidence of:
- Actual consumer confusion
- Market damage within India
To know more about this, click the link below:
Business Lesson:
Even if sales have not started locally, brand conflicts can still create legal exposure, particularly in regulated industries.
Strategic Implications for Businesses
This ruling offers several key strategic insights for companies across industries—not just pharmaceuticals.
1. Invest in Trademark Due Diligence
Before launching a brand:
- Conduct thorough trademark searches
- Evaluate phonetic similarity
- Assess industry-specific risks
Skipping this step can result in:
- Product recalls
- Market delays
- Litigation costs
2. Build Distinctive Brand Identities
Generic or similar-sounding names increase legal vulnerability.
Strong brands should be:
- Unique
- Memorable
- Legally defensible
Distinctiveness is not just branding—it is risk management.
3. Protect Brand Assets Early
Register trademarks before:
- Product launches
- Market expansion
- Export operations
Early protection builds:
- Market trust
- Investor confidence
- Long-term valuation strength
4. Recognize Industry-Specific Risk Levels
Some industries face stricter scrutiny, including:
- Pharmaceuticals
- Healthcare
- Food & beverages
- Chemicals
In these sectors, brand similarity can have safety and compliance consequences.
What This Means for Growing Businesses
Whether you’re:
- Launching a new product
- Entering global markets
- Scaling manufacturing
your brand strategy must include intellectual property risk assessment.
Ignoring IP considerations can lead to:
- Product rebranding costs
- Supply chain disruptions
- Loss of customer trust
Forward-thinking businesses treat IP as a core business asset—not just a legal requirement.
Conclusion: Branding Is a Business Asset, Not Just a Name
The Bombay High Court’s decision reinforces a powerful commercial reality:
Brand identity is one of the most valuable assets a company owns—and one of the most vulnerable if not protected properly.
For businesses, the takeaway is clear:
- Choose distinctive names
- Protect them early
- Monitor market risks
- Treat IP strategy as part of business growth
In today’s competitive marketplace, strong branding backed by strong IP protection is a decisive competitive advantage.